<DOC>
	<DOCNO>NCT00128011</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity new formulation locally-produced bivalent , ( O-1 O-139 ) kill whole cell oral cholera vaccine among Vietnamese adult .</brief_summary>
	<brief_title>Safety Immunogenicity New Formulation Bivalent Killed , Whole-Cell Oral Cholera Vaccine</brief_title>
	<detailed_description>Cholera remain serious public health problem worldwide . In mid-1980s follow technology transfer Sweden , Vietnamese scientist develop produce oral kill monovalent cholera vaccine Vietnam â€™ public health program . A 2-dose regimen vaccine show safe efficacious . Subsequently , bivalent vaccine develop contain newly emergent O139 V. cholerae . This vaccine several advantage exist Swedish vaccine . It confer protection El Tor biotype young child , considerably less expensive , require buff administration require strict cold chain requirement . However , vaccine license use country Vietnam . In order make vaccine available country , IVI provide technical assistance produce vaccine follow WHO Good Manufacturing Practices standard . A new formulation current oral cholera vaccine produce follow guideline . Since vaccine slightly different previous vaccine , study necessary demonstrate safety immunogenicity local licensure large Phase III study country .</detailed_description>
	<mesh_term>Cholera</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy nonpregnant adult Available study area 1 month Diarrhea past week Antibiotic use past week Intake antidiarrheal medicine past week One episodes diarrhea abdominal pain last 2 week past 6 month Abdominal pain , nausea , vomit , loss appetite generalize ill feel past 24 hour Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>watery diarrhea</keyword>
	<keyword>cholera vaccine</keyword>
</DOC>